Cancer News and Research

Latest Cancer News and Research

SBI urges Congress to exclude the USPSTF guidelines from health care legislation

Several sections of Senate health care reform legislation contain language stipulating that insurance entities such as private insurers, Medicare and Medicaid would only be required to cover services receiving a specific grade from the U.S. Preventative Services Task Force. Presently, this would exclude mammography services for women 40-49, would only require coverage of biennial (every other year) coverage for women 50-74, and exclude coverage for those 74 and older.

25 Nov 2009

Study may pave way for potential drug targets in lung cancer treatment

Researchers from Boston University School of Medicine (BUSM) and the Boston University Biomedical Engineering Department have identified a number of proteins whose activation allows them to distinguish between cancer and normal cells with almost 97 percent accuracy.

25 Nov 2009

Positive Phase II/III clinical data from ChemoCentryx' PROTECT-1 Traficet-EN trial

ChemoCentryx, Inc., announced today that Phase II/III clinical data from the Company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn's disease demonstrated clinical efficacy with a favorable safety and tolerability profile. The

25 Nov 2009

Clinical data on ImmunoGen's TAP compounds to be presented at the 51st ASH meeting

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that presentations of clinical data for three product candidates employing its Targeted Antibody Payload (TAP) technology will be made at the 51st American Society of Hematology (ASH) Annual Meeting and Exposition to be held in New Orleans, LA, on December 5-8, 2009.

25 Nov 2009

Ambit Biosciences presents data evaluating FLT3 inhibitor in AML at the 51st ASH meeting

Ambit Biosciences Corporation announced today that there will be multiple presentations evaluating AC220, a novel second generation FLT3 inhibitor, in AML at the 51st American Society of Hematology Annual Meeting (ASH) to be held in New Orleans, LA ,December 5-8, 2009. An oral presentation will highlight results from an ongoing clinical Phase I monotherapy safety study in adults with acute myeloid leukemia (AML).

25 Nov 2009

Researchers uncover atomic-level action of ring-shaped protein motors

The atomic-level action of a remarkable class of ring-shaped protein motors has been uncovered by researchers with the Lawrence Berkeley National Laboratory (Berkeley Lab) using a state-of-the-art protein crystallography beamline at the Advanced Light Source (ALS).

25 Nov 2009

Health watch: When you eat just as vital to what you eat

When you eat may be just as vital to your health as what you eat, found researchers at the Salk Institute for Biological Studies. Their experiments in mice revealed that the daily waxing and waning of thousands of genes in the liver—the body's metabolic clearinghouse—is mostly controlled by food intake and not by the body's circadian clock as conventional wisdom had it.

25 Nov 2009

Emerging cancer vaccines: Forecasts, new developments and pipeline analysis

The H1N1 vaccine has spurred media interest in vaccines, as well as predictions of vaccines for a host of new diseases. According to Kalorama Information, certain cancers may be added to the list of diseases for which vaccinations will be employed.

25 Nov 2009

New Brunswick's colorectal cancer screening program lauded by CCAC

The Colorectal Cancer Association of Canada (CCAC) applauds the decision of the New Brunswick's Minister of Health Mary Schryer to implement a province wide colorectal cancer screening program and to provide funding for Avastin (bevacizumab) for patients with metastatic colorectal cancer.

25 Nov 2009

Study: GSTP gene protects against bowel cancer

CANCER RESEARCH UK scientists have shown that deleting a single gene can increase the average number of tumours in the bowel by 50-fold, according to research published in PNAS today.

25 Nov 2009

Alpha-fetoprotein, a well-tolerated agent for treatment and prevention of breast cancer

Researchers have found that hormones produced during pregnancy induce a protein that directly inhibits the growth of breast cancer. This protein, alpha-fetoprotein (AFP), may serve as a viable, well-tolerated agent for the treatment and prevention of breast cancer, according to findings published in Cancer Prevention Research, a journal of the American Association for Cancer Research.

25 Nov 2009

Researchers develop new device to detect skin cancer

Researchers at Ben-Gurion University of the Negev are developing a new device that detects cancerous skin tumors, including melanomas that aren't visible to the naked eye.

25 Nov 2009

Study shows 95 percent of radiation oncologists use FDG-PET, MRI and 4DCT to locate cancer

A recent study shows that 95 percent of radiation oncologists use advanced imaging techniques such as positron emission tomography (FDG-PET), magnetic resonance imaging (MRI), and 4-dimensional computed tomography (4DCT) for target delineation (to locate the tumor and other areas at risk for having cancer), according to an article in the December issue of the Journal of the American College of Radiology, (JACR, www.jacr.org).

25 Nov 2009

Initiation of Phase II clinical trial to evaluate the efficacy of BN83495 announced

Ipsen today announced the initiation of an international, multi-center, controlled, randomized Phase II clinical trial to evaluate the safety and efficacy of BN83495, its investigational first-in-class steroid sulfatase (STS) inhibitor, in advanced endometrial cancer.

25 Nov 2009

Multiple presentations from clinical and preclinical studies of ISTODAX to be presented

Gloucester Pharmaceuticals today announced multiple presentations from clinical and preclinical studies of ISTODAX® (romidepsin) at the upcoming 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, Louisiana, at the Ernest N. Morial Convention Center, December 5 – 8, 2009.

25 Nov 2009

Bioniche Life Sciences announces the issuance of MCC patents in Japan

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced the issuance of a number of patents in Japan for its proprietary Mycobacterial Cell Wall-DNA Complex (MCC) composition.

25 Nov 2009

Positive efficacy data from Phase 2 study of AEZS-108 announced

AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide conjugate, AEZS-108 (formerly AN-152), in patients with advanced or recurrent endometrial cancer.

25 Nov 2009

New biodegradable drug-eluting fibers advance stent technology and brain surgery

Stents that keep weakened and flabby arteries from collapsing have been true life-savers. But after six months, those stents are no longer needed -- once the arteries are strengthened, they become unnecessary. Previously, doctors had no choice but to leave them in place.

25 Nov 2009

Faulty enzyme may contribute to malignant brain tumour formation

Around 70 per cent of people with a type of brain tumour - called a low-grade glioma - have a faulty version of an enzyme called IDH1. The mutation is also found in a significant proportion of patients with acute myeloid leukaemia.

25 Nov 2009

Guardian Life Insurance Company of America continues its present coverage guidelines for mammography screenings

The Guardian Life Insurance Company of America (Guardian), one of the largest mutual life insurers and a leading provider of employee benefits for small and mid-sized companies, today announced that the company will continue to follow its current insurance coverage guidelines for mammography screenings.

25 Nov 2009

Cancer News and Research

Latest Cancer News and Research

SBI urges Congress to exclude the USPSTF guidelines from health care legislation

Study may pave way for potential drug targets in lung cancer treatment

Positive Phase II/III clinical data from ChemoCentryx' PROTECT-1 Traficet-EN trial

Clinical data on ImmunoGen's TAP compounds to be presented at the 51st ASH meeting

Ambit Biosciences presents data evaluating FLT3 inhibitor in AML at the 51st ASH meeting

Researchers uncover atomic-level action of ring-shaped protein motors

Health watch: When you eat just as vital to what you eat

Emerging cancer vaccines: Forecasts, new developments and pipeline analysis

New Brunswick's colorectal cancer screening program lauded by CCAC

Study: GSTP gene protects against bowel cancer

Alpha-fetoprotein, a well-tolerated agent for treatment and prevention of breast cancer

Researchers develop new device to detect skin cancer

Study shows 95 percent of radiation oncologists use FDG-PET, MRI and 4DCT to locate cancer

Initiation of Phase II clinical trial to evaluate the efficacy of BN83495 announced

Multiple presentations from clinical and preclinical studies of ISTODAX to be presented

Bioniche Life Sciences announces the issuance of MCC patents in Japan

Positive efficacy data from Phase 2 study of AEZS-108 announced

New biodegradable drug-eluting fibers advance stent technology and brain surgery

Faulty enzyme may contribute to malignant brain tumour formation

Guardian Life Insurance Company of America continues its present coverage guidelines for mammography screenings

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Cancer News and Research

Latest Cancer News and Research

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in